Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867070 | 0.92 | SLC6A9 (0.51) | SLC6A9KCNH2KMT2AGAAMEN1 | |
| SCHEMBL866480 | 0.91 | SLC6A9 (0.55) | SLC6A9KCNH2KMT2AGAAMEN1 | |
| SCHEMBL867925 | 0.89 | SLC6A9 (0.50) | SLC6A9KCNH2KMT2AGAAMEN1 | |
| SCHEMBL867072 | 0.89 | SLC6A9 (0.53) | SLC6A9KCNH2KMT2AGAAMEN1 | |
| SCHEMBL627042 | 0.87 | SLC6A9 (0.54) | SLC6A9KCNH2KMT2AGAAMEN1 | |
| SCHEMBL867167 | 0.86 | SLC6A9 (0.52) | SLC6A9KCNH2KMT2AGAAMEN1 | |
| SCHEMBL866686 | 0.86 | SLC6A9 (0.49) | SLC6A9KCNH2KMT2AGAAMEN1 | |
| SCHEMBL867020 | 0.85 | SLC6A9 (0.49) | SLC6A9KCNH2KMT2AGAAMEN1 | |
| SCHEMBL622095 | 0.85 | SLC6A9 (0.51) | SLC6A9KCNH2KMT2AGAAMEN1 | |
| SCHEMBL866668 | 0.85 | SLC6A9 (0.49) | SLC6A9KCNH2KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | US | claimed |
| US-9238619-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-19 | — | — | US | disclosed |
| US-9238619-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-19 | — | — | US | disclosed |
| US-8877794-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877794-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | SLC6A9 30/4885KCNH2 299/4885KMT2A 682/4885 |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | SLC6A9 30/4885KCNH2 299/4885KMT2A 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.